Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)...

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)...


Oct 22, 2018-- Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo and Yervoy , versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 48 months, four-year overall survival rates were 53% for the Opdivo plus Yervoy combination, 46% for Opdivo alone, and 30% for Yervoy alone.



from Biotech News